Skip to content
MedsAcross

Molecule

Iothalamate

Also known as iothalamate meglumine
Available on requestContrast media and diagnostics
Presentations
1
Brands
1
Manufacturers
1
Available from stock
0

Iothalamate is a radiographic contrast agent indicated in retrograde cystography and cystourethrography. It is available as injection for ureteral use. MedsAcross supplies Iothalamate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Key facts

Pharmacological class
Radiographic Contrast Agent, X-Ray Contrast Activity
ATC classification
V08AA04 Iothalamate · Iodinated contrast, subgroup V08AA
US FDA first approval
16 August 1962
EU status
Not recorded
Orphan designation
Not recorded
WHO essential medicine
Not recorded
India (CDSCO)
Not yet confirmed against CDSCO approval lists
Routes
Ureteral
Dosage forms
Injection
Identifiers
UNII 16CHD79MIXRxCUI 5970CAS 2276-90-6DrugBank DB09133Q6064129

Clinical information

From the regulator-approved product information. Each section names its source.

Dosing overview

Patient Preparation Unless contraindicated, an appropriate laxative is given the night before the examination. Radiographic Technique The radiographic procedure normally employed for cystography and cystourethrography should be employed. A preliminary radiograph is recommended before the contrast agent is administered. Administration Sterile catherization is essential. Cysto-Conray II may be introduced by gravity flow using an appropriate venoclysis set or by syringe. Excessive pressure should be avoided with any method of administration. Usual Dosage Cystography and Cystourethrography – Either Conray 43 supplied at 43% w/v or Cysto-Conray II supplied at a 17.2% w/v concentration may be used for these procedures. The desired concentration will vary depending upon the patient’s size and age and also with the technique and equipment used.

Source: US FDA prescribing information

Warnings and precautions

NOT FOR INTRAVASCULAR ADMINISTRATION NOT FOR INTRATHECAL USE SEVERE ADVERSE EVENTS – INADVERTENT INTRATHECAL ADMINISTRATION: Serious adverse reactions have been reported due to the inadvertent intrathecal administration of iodinated contrast media that are not indicated for intrathecal use. These serious adverse reactions include: death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. Special attention must be given to ensure that this drug product is not administered intrathecally.

Source: US FDA prescribing information

Side effects

Irritation of the bladder or ureter, common to some degree to all contrast media administered for retrograde urographic procedures, may occasionally occur. As with all contrast media, intravasation may lead to hypersensitivity reactions such as a sense of warmth, flushing, sneezing, sweating, chills, fever, urticaria, laryngeal edema, bronchospasm, hypertension, hypotension, cardiac arrhythmias and cardiac arrest. Adverse reactions associated with procedural technique include injury to the urethra, bladder, ureter, and introduction of infection. In the event of serious or anaphylactoid reactions, it should be kept in mind that the reactions known to occur with intravenous administration of radiopaque contrast materials are possible.

Source: US FDA prescribing information

Storage

Store at 20° to 25°C (68° to 77°F). If this occurs, the containers should be brought to room temperature. This product is sensitive to light and must be protected from strong daylight or direct exposure to the sun.

Source: US FDA prescribing information

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

All presentations

1 presentations of Iothalamate, sorted by availability.

MedicineManufacturerRegisterAvailability
Cysto-Conray II 43000 mg/250 mL injectionUreteralLiebel-FlarsheimUS FDAAvailable on request

Brands by market

1 brand names across 1 markets.

Brand names by country

United States

Manufacturers

Regulatory status

Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.

RegisterStatusSource
US FDAFirst approved 16 August 1962Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Questions and answers

Is Iothalamate available for export from India?

Yes, on request. MedsAcross lists 1 presentations of Iothalamate and sources them for licensed hospitals, importers and physicians against valid import documents.

What brand names does Iothalamate have?

The catalogue lists 1 brand names for Iothalamate, including Cysto-Conray II.

Is Iothalamate approved by the US FDA?

Yes. The US FDA first approved Iothalamate on 16 August 1962, according to Drugs@FDA.

Does Iothalamate need cold chain shipping?

No listed presentation of Iothalamate is recorded as needing a cold chain. Storage conditions are shown on each presentation page.

Which ATC class is Iothalamate in?

Iothalamate is classified under ATC code V08AA04 (Iothalamate).

References

  1. Cysto-Conray II prescribing information (Liebel-Flarsheim). U.S. National Library of Medicine, DailyMed. Retrieved 31 December 2020

Request Iothalamate for export supply

Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.